{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:31:57Z","timestamp":1793467917812,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s13760-025-02766-3","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T20:11:42Z","timestamp":1744402302000},"page":"999-1006","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy of ocrelizumab versus rituximab in patients with relapsing-remitting multiple sclerosis"],"prefix":"10.1007","volume":"125","author":[{"given":"Nesma","family":"Mounir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevin","family":"Shalaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed I.","family":"Hegazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmeen","family":"Kishk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem","family":"Shehata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaimaa Abdalaleem","family":"Abdalgeleel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Mohammed","family":"Abdulrahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahla","family":"Merghany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,12]]},"reference":[{"issue":"14","key":"2766_CR1","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C et al (2020) Rising prevalence of multiple sclerosis worldwide: insights from the atlas of MS, third edition. Mult Scler 26(14):1816\u20131821","journal-title":"Mult Scler"},{"issue":"3","key":"2766_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL et al (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376(3):221\u2013234","journal-title":"N Engl J Med"},{"issue":"3","key":"2766_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X et al (2017) Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376(3):209\u2013220","journal-title":"N Engl J Med"},{"issue":"7","key":"2766_CR4","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL et al (2008) B-cell depletion with rituximab in relapsing\u2013remitting multiple sclerosis. N Engl J Med 358(7):676\u2013688","journal-title":"N Engl J Med"},{"issue":"4","key":"2766_CR5","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/ana.21867","volume":"66","author":"K Hawker","year":"2009","unstructured":"Hawker K et al (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo\u2010controlled multicenter trial. Ann Neurol 66(4):460\u2013471","journal-title":"Ann Neurol"},{"issue":"20","key":"2766_CR6","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","volume":"87","author":"J Salzer","year":"2016","unstructured":"Salzer J et al (2016) Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology 87(20):2074\u20132081","journal-title":"Neurology"},{"key":"2766_CR7","doi-asserted-by":"crossref","unstructured":"Yamout BI et al (2018) Safety and efficacy of rituximab in multiple sclerosis: a retrospective observational study. Journal of immunology research, 2018","DOI":"10.1155\/2018\/9084759"},{"issue":"12","key":"2766_CR8","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1177\/1352458519872889","volume":"26","author":"C Zecca","year":"2020","unstructured":"Zecca C et al (2020) Treatment of multiple sclerosis with rituximab: a multicentric Italian\u2013Swiss experience. Multiple Scler J 26(12):1519\u20131531","journal-title":"Multiple Scler J"},{"issue":"7","key":"2766_CR9","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1007\/s00415-022-10989-0","volume":"269","author":"C Alcal\u00e1","year":"2022","unstructured":"Alcal\u00e1 C et al (2022) Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study. J Neurol 269(7):3676\u20133681","journal-title":"J Neurol"},{"key":"2766_CR10","unstructured":"Roos I et al (2022) A non-inferiority study of rituximab versus ocrelizumab in relapsing-remitting multiple sclerosis. in MULTIPLE SCLEROSIS JOURNAL. SAGE PUBLICATIONS LTD 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND"},{"issue":"8","key":"2766_CR11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/jamaneurol.2023.1625","volume":"80","author":"I Roos","year":"2023","unstructured":"Roos I et al (2023) Rituximab vs Ocrelizumab in Relapsing-Remitting multiple sclerosis. JAMA Neurol 80(8):789\u2013797","journal-title":"JAMA Neurol"},{"issue":"9","key":"2766_CR12","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1093\/brain\/awac016","volume":"145","author":"FD Lublin","year":"2022","unstructured":"Lublin FD et al (2022) How patients with multiple sclerosis acquire disability. Brain 145(9):3147\u20133161","journal-title":"Brain"},{"issue":"11","key":"2766_CR13","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444\u20131444","journal-title":"Neurology"},{"key":"2766_CR14","doi-asserted-by":"crossref","unstructured":"Vollmer B et al (2023) Comparison of Ocrelizumab and rituximab over 2 years of treatment for multiple sclerosis. ACTRIMS forum 2023 - Poster presentations. Multiple Scler J 29(2_suppl): 18\u2013242","DOI":"10.1177\/13524585231169437"},{"key":"2766_CR15","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1007\/s13311-021-01037-2","volume":"18","author":"A Zangh\u00ec","year":"2021","unstructured":"Zangh\u00ec A et al (2021) Exit strategies in natalizumab-treated RRMS at high risk of progressive multifocal leukoencephalopathy: a multicentre comparison study. Neurotherapeutics 18:1166\u20131174","journal-title":"Neurotherapeutics"},{"issue":"2","key":"2766_CR16","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/ene.15142","volume":"29","author":"L Pontieri","year":"2022","unstructured":"Pontieri L et al (2022) Ocrelizumab treatment in multiple sclerosis: a Danish population-based cohort study. Eur J Neurol 29(2):496\u2013504","journal-title":"Eur J Neurol"},{"key":"2766_CR17","doi-asserted-by":"publisher","first-page":"592304","DOI":"10.3389\/fneur.2020.592304","volume":"11","author":"AP Sempere","year":"2021","unstructured":"Sempere AP et al (2021) Ocrelizumab in multiple sclerosis: a real-world study from Spain. Front Neurol 11:592304","journal-title":"Front Neurol"},{"issue":"2","key":"2766_CR18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/acn3.51282","volume":"8","author":"E Fernandez-Diaz","year":"2021","unstructured":"Fernandez-Diaz E et al (2021) Real\u2010world experience of Ocrelizumab in multiple sclerosis in a Spanish population. Ann Clin Transl Neurol 8(2):385\u2013394","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"2766_CR19","doi-asserted-by":"publisher","first-page":"e0197415","DOI":"10.1371\/journal.pone.0197415","volume":"13","author":"B Scotti","year":"2018","unstructured":"Scotti B et al (2018) Effectiveness and safety of rituximab in multiple sclerosis: an observational study from Southern Switzerland. PLoS ONE 13(5):e0197415","journal-title":"PLoS ONE"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-025-02766-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-025-02766-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-025-02766-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T11:35:19Z","timestamp":1757158519000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-025-02766-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,12]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2766"],"URL":"https:\/\/doi.org\/10.1007\/s13760-025-02766-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4752481\/v1","asserted-by":"object"}]},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,12]]},"assertion":[{"value":"16 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval was obtained from the \u201cResearch ethical committee (REC) Cairo University Faculty of Medicine, Code (MS-165-2022).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent for publication"}}]}}